Chlorpromazine Clinical Guidelines

Dosing and Efficacy

The optimal dosing range for chlorpromazine is 12.5-400 mg/day, with most modern practice favoring the lower end of this spectrum, as recommended by the American Society of Clinical Oncology 1
For terminal restlessness in palliative care, 12.5 mg IV every 4-12 hours or 25 mg PR every 4-12 hours provides effective symptom control, according to the American Society of Clinical Oncology 1
Extrapyramidal symptoms occur more frequently with chlorpromazine than with atypical antipsychotics; monitor for dystonic reactions, akathisia, and pseudo-parkinsonism, as suggested by the American College of Emergency Physicians 1 and the American College of Emergency Physicians 2

For acute agitation in emergency settings, 12.5 mg IM every 4-6 hours is recommended, with similar efficacy to droperidol by 60 minutes, as stated by the American College of Emergency Physicians 2
Chlorpromazine shows slower onset than droperidol but similar efficacy by 60 minutes for acute agitation, according to the American College of Emergency Physicians 2
Consider combining chlorpromazine with lorazepam for enhanced effect in severe agitation, as suggested by the American College of Emergency Physicians 2
For chemotherapy-induced nausea, chlorpromazine is not first-line; use only for breakthrough symptoms after 5-HT3 antagonists fail, as recommended by the National Comprehensive Cancer Network 3
Prochlorperazine (related phenothiazine) is preferred over chlorpromazine for antiemetic purposes, according to the National Comprehensive Cancer Network 3

Start with lowest effective doses (12.5-25 mg) for elderly and debilitated patients, as recommended by the American Society of Clinical Oncology 1
Elderly patients have increased risk of falls due to orthostatic hypotension and sedation, and higher sensitivity to anticholinergic effects and extrapyramidal symptoms, according to the American Society of Clinical Oncology 1

The American Academy of Pediatrics recommends monitoring for QTc prolongation, orthostatic hypotension, and sinus tachycardia when using chlorpromazine, due to its potential to cause cardiovascular side effects 4
The European Heart Journal suggests that combining chlorpromazine with other QT-prolonging medications significantly increases arrhythmia risk, and should be avoided without careful monitoring 4, 5
Neurological side effects such as dystonic reactions, extrapyramidal symptoms, and anticholinergic effects may occur with chlorpromazine use, and should be monitored 4

The American Heart Association implies that alternative agents like metoclopramide, baclofen, or gabapentin may be considered if oral therapy with chlorpromazine fails, or if long-term therapy is anticipated 4, 5

The National Comprehensive Cancer Network (NCCN) recommends keeping diphenhydramine 25–50 mg readily available to treat acute dystonic reactions that may occur with chlorpromazine therapy. 6